Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7120719 | 1.00 | ADRB3 (0.49) | ADRB3CYP2D6HTR2ALTB4RLTB4R2 | |
| SCHEMBL7111944 | 0.89 | ADRB3 (0.44) | ADRB3CYP2D6HTR2ALTB4RLTB4R2 | |
| SCHEMBL7117639 | 0.89 | ADRB3 (0.44) | ADRB3CYP2D6HTR2ALTB4RLTB4R2 | |
| SCHEMBL7171059 | 0.87 | KCNH2 (0.46) | ADRB3ALDH1A1 | |
| SCHEMBL7171047 | 0.87 | KCNH2 (0.46) | ADRB3ALDH1A1 | |
| SCHEMBL7115609 | 0.86 | ADRB3 (0.62) | ADRB3CYP2D6ALDH1A1CYP1A2MAPT | |
| SCHEMBL7120397 | 0.85 | ADRB3 (0.42) | ADRB3MAPT | |
| SCHEMBL7113390 | 0.85 | ADRB3 (0.37) | ADRB3CYP2D6HTR2ALTB4RLTB4R2 | |
| SCHEMBL7120405 | 0.85 | ADRB3 (0.42) | ADRB3MAPT | |
| SCHEMBL7113384 | 0.85 | ADRB3 (0.37) | ADRB3CYP2D6HTR2ALTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | WYETH | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885CYP2D6 647/4885HTR2A 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.